We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Regeneron Pharmaceuticals Inc | NASDAQ:REGN | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 892.48 | 869.00 | 906.74 | 0 | 10:10:20 |
From Apr 2019 to Apr 2024
By Matt Grossman
Regeneron Pharmaceuticals Inc. and Sanofi said Monday they have begun clinical trials to test a drug's efficacy in treating patients with severe Covid-19 cases.
The Phase 2/3 trial, beginning at hospitals in New York, will enroll as many as 400 patients to test the companies' sarilumab drug in patients with severe disease caused by the new coronavirus. The drug is an antibody that inhibits the interleukin-6 pathway, which may have a part in lung inflammation in patients with the disease, the companies said.
Preliminary results from a study in China showed that a similar approach using a different drug were promising, the companies said.
Write to Matt Grossman at matt.grossman@wsj.com
(END) Dow Jones Newswires
March 16, 2020 08:42 ET (12:42 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
1 Year Regeneron Pharmaceuticals Chart |
1 Month Regeneron Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
